Glycoxidation and inflammation in chronic haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 18, Issue 12, 2003, Pages 2577-2581

  Kalousová, Marta ^a   Sulková, Sylvie ^a   Fialová, Lenka ^a   Soukupová, Jiřina ^a   Malbohan, Ivan Matouš ^a   Špaček, Pavel ^b   Braun, Martin ^b   Mikulíková, Ludmila ^a   Fořtová, Magdaléna ^a   Hořejší, Magdaléna ^a   Tesař, Vladimír ^a   Zima, Tomáš ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Advanced glycation end products; Advanced oxidation protein products; Carbonyl stress; Haemodialysis; Inflammation; Oxidative stress

Indexed keywords

ACUTE PHASE PROTEIN; ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; BIOCHEMICAL MARKER; FIBRINOGEN; OROSOMUCOID; PENTOSIDINE; PREGNANCY ASSOCIATED PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEALTH STATUS; HEMODIALYSIS; HUMAN; IMMUNOLOGICAL PARAMETERS; INFLAMMATION; MALE; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN METABOLISM; STATISTICAL SIGNIFICANCE;

ACUTE-PHASE PROTEINS; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNE SYSTEM DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; RENAL DIALYSIS;

EID: 10744233132     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg404     Document Type: Article

References (20)

1. Schwedler S, Schinzel R, Vaith P, Wanner C. Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship? Kidney Int 2001; 59 [Suppl. 78]: S32-S36
2. Miyata T, Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of 'carbonyl stress' in long-term uremic complications. Kidney Int 1999; 55: 389-399
3. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658
4. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998; 37: 586-600
5. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313
6. Witko-Sarsat V, Friedlander M, Nguen-Khoa T et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532
7. Deppisch RM, Beck W, Goehl H, Ritz E. Complement components as uremic toxins and their potential role as mediators of microinflammation. Kidney Int 2001; 59: S271-S277
8. Acosta J, Hettinga J, Fluckinger R et al. Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci USA 2000; 97: 5450-5455
9. Spaček P, Adam M. Method for pentosidine determination in urine, serum and tissues as a marker of glycation and oxidation loading of the organism. J Liquid Chromatogr Rel Technol 2002; 25: 1805-1818
10. Henle T, Deppisch R, Beck W, Hergesell O, Hansch G, Ritz E. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogenity of AGE compounds. Nephrol Dial Transplant 1999; 14: 1968-1975
11. Munch G, Kies R, Wessel A et al. Determination of advanced glycation and products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 1997; 35: 669-677
12. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates NE-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999; 104: 103-113
13. Sebeková K, Podracká L, Heidland A, Schinzel R. Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation-are they inter-related? Clin Nephrol 2001; 56: S21-26
14. Schwedler BS, Metzger T, Schinzel R, Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002; 62: 301-310
15. Miyata T, Ishiguro N, Yasuda Y et al. Increased pentosidine, an advanced glycation end product, in plasma and synovial fiuid from patients with rheumatoid arthritis and its relationship with inflammatory markers. Biochem Biophys Res Commun 1998; 244: 45-49
16. Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 2002; 162: 221-225
17. Kalousova M, Zima T, Tesar V, Lachmanová J. Advanced glycation end products and advanced oxidation protein products in hemodialysis patients. Blood Purif 2002; 20: 531-536
18. Christiansen MS, Hommel E, Magid E, Feldt-Rasmussen B. Orosomucoid in urine predicts cardiovascular and overall mortality in patients with type II diabetes. Diabetologia 2002; 45: 115-120
19. Lawrence JB, Oxvig C, Overgaard MT et al. The insulin-like growth factor-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy associated plasma protein-A. Proc Natl Acad Sci USA 1999; 96: 3149-3153
20. Bayes-Genis A, Conover CA, Overgaard MT et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001; 345: 1022-1029